Product Description
Manganese(II) chloride tetrahydrate is a hydrate that is the tetrahydrate form of manganese(II) chloride. It has a role as a nutraceutical and a MRI contrast agent. It is a hydrate, an inorganic chloride and a manganese coordination entity. It contains a manganese(II) chloride. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Manganese-chloride-tetrahydrate)
Mechanisms of Action: Contrast Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Transdermal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Chile | Croatia | France | Hungary | Japan | Malaysia | Norway | Poland | South Africa | Sweden | Taiwan | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: CMC Contrast AB
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany, Italy, Netherlands
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Dermatitis, Allergic Contact|Dermatitis, Atopic|Dermatitis, Contact
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-507972-35-00 | P3 |
Unknown Status |
Dermatitis, Atopic|Dermatitis, Allergic Contact|Dermatitis, Contact |
2026-01-01 |
|
| 2023-507972-35-01 | P3 |
Unknown Status |
Dermatitis, Contact|Dermatitis, Allergic Contact |
2026-01-01 |
|
| SPARKLE | P3 |
Completed |
Unknown |
2022-03-31 |